Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...113114115116117118119120121122123...136137»
  • ||||||||||  azathioprine orodispersible / Generic mfg.
    Journal:  Coexistence of myasthenia gravis with hypokalemic periodic paralysis: a rare presentation. (Pubmed Central) -  Feb 21, 2020   
    Patient was finally discharged home on oral steroids, pyridostigmine and azathioprine. In a patient presenting with hypokalemic weakness, the suspicion of a second disorder should be very high if weakness fails to resolve following correction of hypokalemia.
  • ||||||||||  Review, Journal:  Neuromuscular Junction Disorders and Floppy Infant Syndrome: A Comprehensive Review. (Pubmed Central) -  Feb 21, 2020   
    Depending on the underlying causative disorder leading to the presence of floppy infant syndrome, the treatment will vary considerably. Treatment of the underlying causative syndrome resulting in the presentation of floppy infant syndrome deals with the symptoms of hypotonia, and as a result, the decreased muscle tone, diminished tendon reflexes, any feeding or respiratory difficulties diminish.
  • ||||||||||  Clinical, Journal:  Ocular Weakness in Myasthenia Gravis: Changes in Affected Muscles are a Distinct Clinical Feature. (Pubmed Central) -  Feb 20, 2020   
    Changes in the gaze directions in which diplopia occurs or ptosis side occur frequently in MG. In diagnostically challenging cases, we recommend testing ptosis and diplopia in multiple gaze directions for 30-60 seconds during at least two follow-up visits to maximize the chance of observing changes in ocular weakness patterns.
  • ||||||||||  olanzapine / Generic mfg., lithium / Generic mfg., amisulpride / Generic mfg.
    [VIRTUAL] Lithium induced Myasthenia Gravis: A Case Report (Station 04) -  Feb 20, 2020 - Abstract #EPA2020EPA_410;    
    Objectives: The patient was using olanzapine, amisulpride and lithium bicarbonate more than a month when he administered and the following neurological and laboratory assessments were consistent with myasthenia gravis (MG). Clinicians should therefore be cautious for the detection of myasthenic symptoms related with lithum therapy especially in bipolar disorder and schizoaffective disorder.
  • ||||||||||  Review, Journal:  MMP-mediated modulation of ECM environment during axonal growth and NMJ development. (Pubmed Central) -  Feb 19, 2020   
    Furthermore, the increased level of several MMPs in myasthenia gravis (MG) patient suggest the pathophysiological mechanisms of MMP-mediated proteolytic degradation in MG pathogenesis. Finally, we speculate on potential major future directions for studying the regulatory functions of MMP-mediated ECM remodeling in axonal growth and NMJ development.
  • ||||||||||  Clinical, Review, Journal:  Navigating monoclonal antibody use in breastfeeding women: Do no harm or do little good? (Pubmed Central) -  Feb 15, 2020   
    We summarize how pregnancy affects the trajectory of these diseases and explore the benefit derived from mAb therapies. We posit that as neurologists, we are uniquely poised to lead the study of peripartum safety for the mAbs now on the market and provide a framework for their future study.
  • ||||||||||  Journal:  Associations of BAFF rs2893321 polymorphisms with myasthenia gravis susceptibility. (Pubmed Central) -  Feb 15, 2020   
    We posit that as neurologists, we are uniquely poised to lead the study of peripartum safety for the mAbs now on the market and provide a framework for their future study. Genetic variations of rs2893321 in BAFF might be associated with susceptibility to MG in the Chinese Han population.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, efgartigimod IV (ARGX-113 IV) / argenx, Broteio
    Review, Journal:  Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care Unit. (Pubmed Central) -  Feb 15, 2020   
    Efgartigimod showed great promise in a phase 2 safety and efficacy trial in the treatment of stable generalized myasthenia gravis...While there are some newer immunotherapies available, few have been studied in the acute setting. However, with the advent of new immunotherapies and biologics, changes in these approaches may be on the horizon.
  • ||||||||||  Journal:  Myasthenia Gravis: Do the Subtypes Matter? (Pubmed Central) -  Feb 15, 2020   
    However, with the advent of new immunotherapies and biologics, changes in these approaches may be on the horizon. No abstract available
  • ||||||||||  Journal:  Lambert-Eaton myasthenic syndrome and merkel cell carcinoma. (Pubmed Central) -  Feb 14, 2020   
    We provide a full report and longitudinal clinical follow-up of a case of LEMS occurring with MCC. We also review the literature on paraneoplastic syndromes associated with MCC and other nonpulmonary small cell carcinomas.
  • ||||||||||  Case report: Myasthenia Gravis in under 26 months () -  Feb 11, 2020 - Abstract #ISPRM2020ISPRM_1503;    
    The involvement of a multidisciplinary team and importance of comprehensive counseling should be provided to women with epilepsy, MG and MS. Myasthenia Gravis is a disease that should be considered within differential diagnoses in children with weakness of the ocular musculature, as it has a simple treatment that significantly improves the quality of life of patients.
  • ||||||||||  valacyclovir / Generic mfg.
    A Rare Case of Limb Paresis From The Varicella Zoster Virus () -  Feb 11, 2020 - Abstract #ISPRM2020ISPRM_375;    
    Varicella Zoster Virus PCR was positive and the patient was initiated on a one-week course of valacyclovir...There is no documented incidence of segmental limb paresis although, it is extremely rare given only a few documented case reports in the literature. Conclusions : Segmental zoster paresis is a very rare complication of herpes zoster infection and should be considered in a differential diagnosis of individual limb pain and weakness, with or without a rash, especially in an immunocompromised patient.
  • ||||||||||  Clinical, Journal:  Early extubation after thymectomy is good for the patients with myasthenia gravis. (Pubmed Central) -  Feb 9, 2020   
    Conclusions : Segmental zoster paresis is a very rare complication of herpes zoster infection and should be considered in a differential diagnosis of individual limb pain and weakness, with or without a rash, especially in an immunocompromised patient. Our analysis of patients with MG who received thymectomy procedures indicated that early extubation was associated with improved clinical outcomes, in particular with reduced risk of postoperative pulmonary infection and reduced ICU stay.
  • ||||||||||  [VIRTUAL] CONCURRENCE OF GVHD AND NON-INFECTIOUS NEUROLOGICAL COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) -  Feb 8, 2020 - Abstract #EBMT2020EBMT_1220;    
    Furthermore, when analyzed according to a more natural distribution of occurrence borne out of stricter analysis criteria, a statistically significant association was established between the concurrence of GVHD and certain NCs. This study underscores the importance of accurate reporting of GVHD in a precisely stratified HCT recipient population and increased awareness amongst treating physicians of the above-established associations.
  • ||||||||||  PK/PD data, Preclinical, Journal:  Pharmacokinetics and Tissue Distribution of 3,4-Diaminopyridine in Rats. (Pubmed Central) -  Feb 8, 2020   
    Furthermore, greater than 68% of 3,4-DAP was distributed to the muscle as determined by the ratio of 3,4-DAP distribution calculated from apparent volumes of distribution. Hence, 3,4-DAP may provide for more effective and long-lasting effects.
  • ||||||||||  Clinical, Journal:  Pyridostigmine Suicidal Attempt in a Myasthenia Gravis Patient. (Pubmed Central) -  Feb 7, 2020   
    As the literature on human toxicity with pyridostigmine is scarce, not much data is available on its toxicity. However, prompt and specific management of pyridostigmine toxicity promises safety.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, efgartigimod IV (ARGX-113 IV) / argenx, Broteio
    Journal:  Current pharmacotherapeutic options for myasthenia gravis. (Pubmed Central) -  Feb 7, 2020   
    Manipulation of the immune system can also lead to iatrogenic MG. Although novel treatments can improve care for myasthenia gravis patients, future developments that prevent the production of specific abnormal auto-antibodies are desirable.
  • ||||||||||  Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
    Enrollment closed, Trial completion date, Trial primary completion date:  Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG (clinicaltrials.gov) -  Feb 5, 2020   
    P3,  N=60, Active, not recruiting, 
    No abstract available Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Oct 2019 --> Jan 2020
  • ||||||||||  Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
    Enrollment closed, Trial completion date, Trial primary completion date:  Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) (clinicaltrials.gov) -  Feb 5, 2020   
    P3,  N=70, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Oct 2019 --> Jan 2020 Recruiting --> Active, not recruiting | Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
  • ||||||||||  Journal:  Quantification of human neuromuscular function through optogenetics. (Pubmed Central) -  Feb 1, 2020   
    We demonstrate the utility of this model for basic and translational research by characterizing in real time the functional changes during physiological and pathological processes. Principal This system holds great potential for the study of neuromuscular diseases and drug screening, allowing for the extraction of quantitative functional data from a human, patient-specific system.